 Connection
Pamela Peterson to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Pamela Peterson has written about Angiotensin-Converting Enzyme Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.223 |
|
|
|
-
Peterson PN, Chan PS, Spertus JA, Tang F, Jones PG, Ezekowitz JA, Allen LA, Masoudi FA, Maddox TM. Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program. Circ Heart Fail. 2013 Nov; 6(6):1132-8.
Score: 0.411
-
Peterson PN, Rumsfeld JS, Liang L, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA. Treatment and risk in heart failure: gaps in evidence or quality? Circ Cardiovasc Qual Outcomes. 2010 May; 3(3):309-15.
Score: 0.322
-
Breathett KK, Xu H, Sweitzer NK, Calhoun E, Matsouaka RA, Yancy CW, Fonarow GC, DeVore AD, Bhatt DL, Peterson PN. Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity? Am Heart J. 2022 02; 244:135-148.
Score: 0.180
-
Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008 Apr; 155(4):772-9.
Score: 0.070
-
Bhatt AS, Fonarow GC, Greene SJ, Holmes DN, Alhanti B, Devore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Linganathan K, Joyntmaddox KE, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Vaduganathan M. Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure Registry. J Card Fail. 2024 Feb; 30(2):319-328.
Score: 0.051
-
Pierce JB, Blumer V, Choi S, Hardy NC, Greiner MA, Carnicelli AP, Shen X, Lippmann SJ, Peterson PN, Allen LA, Fonarow GC, Mentz RJ, Greene SJ, O'Brien EC. Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart Failure Among Medicare Beneficiaries Na?ve to Renin-Angiotensin System Inhibitors. Am J Cardiol. 2023 10 01; 204:151-158.
Score: 0.051
-
Vaduganathan M, Greene SJ, Zhang S, Solomon N, Chiswell K, Devore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Mcdermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. J Card Fail. 2022 04; 28(4):554-563.
Score: 0.045
-
Samsky MD, Lin L, Greene SJ, Lippmann SJ, Peterson PN, Heidenreich PA, Laskey WK, Yancy CW, Greiner MA, Hardy NC, Kavati A, Park S, Mentz RJ, Fonarow GC, O'Brien EC. Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. JAMA Cardiol. 2020 03 01; 5(3):292-299.
Score: 0.040
-
Shore S, Jones PG, Maddox TM, Bradley SM, Stolker JM, Arnold SV, Parashar S, Peterson P, Bhatt DL, Spertus J, Ho PM. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction. Heart. 2015 May 15; 101(10):800-7.
Score: 0.028
-
Clarke CL, Grunwald GK, Allen LA, Bar?n AE, Peterson PN, Brand DW, Magid DJ, Masoudi FA. Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013 Nov; 6(6):680-6.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|